This HTML5 document contains 35 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB03155/identifier/pdb/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB03155/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB03155/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/drug/DB03155/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB03155
rdf:type
n3:Drug
n3:group
experimental
owl:sameAs
n6:DB03155 n12:DB03155
dcterms:title
1-(2-Deoxy-2-Fluoro-3-O-Phosphono-Beta-L-Ribofuranosyl)Pyrimidine-2,4(1h,3h)-Dione
adms:identifier
n9:46936585 n10:46507005 n11:DB03155 n13:UMF
n3:IUPAC-Name
n4:271B543F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5445-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5444-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5441-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5442-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5443-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B543D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B543E-363D-11E5-9242-09173F13E4C5 n4:271B543B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B543C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B544B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B544C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5446-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5447-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5449-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5448-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B544A-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5451-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5453-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5454-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5450-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B544F-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5452-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5440-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B544D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B544E-363D-11E5-9242-09173F13E4C5